Denali Therapeutics logo

Denali TherapeuticsNASDAQ: DNLI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 December 2017

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$3.57 B
-38%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector
-54%vs. 3y high
66%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:27:39 GMT
$24.79+$1.29(+5.48%)

Dividend

No data over the past 3 years
$5.00 M$11.62 M

Analysts recommendations

Institutional Ownership

DNLI Latest News

Denali Has A Neurodegenerative Edge Despite Market Skepticism
seekingalpha.com16 November 2024 Sentiment: POSITIVE

Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash position and disciplined financial strategy support its ambitious R&D and commercialization efforts without immediate need for additional funding. Denali's pipeline targets critical neurodegenerative pathways, with promising candidates for lysosomal storage disorders, Parkinson's disease, and neuroinflammation.

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
zacks.com08 November 2024 Sentiment: POSITIVE

DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
zacks.com16 September 2024 Sentiment: POSITIVE

Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
zacks.com04 September 2024 Sentiment: POSITIVE

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.

Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
zacks.com23 July 2024 Sentiment: POSITIVE

Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
investorplace.com08 July 2024 Sentiment: POSITIVE

The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.

Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
zacks.com06 June 2024 Sentiment: POSITIVE

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
zacks.com04 June 2024 Sentiment: POSITIVE

Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Seeking Alpha13 May 2024 Sentiment: POSITIVE

Denali Therapeutics Inc. is currently investigating DNL-310 in a phase 2/3 COMPASS study for patients with MPS II, with enrollment completion anticipated in 2024. The company is in discussions with the FDA's CDER division to pursue the Accelerated Approval pathway for DNL-310 in MPS II. Data on biomarkers and safety from a phase 1/2 study using DNL-126 for MPS IIIA patients is expected by the end of 2024.

Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
Zacks Investment Research09 April 2024 Sentiment: POSITIVE

Denali Therapeutics (DNLI) has experienced positive changes in earnings estimates in the last month and is part of a robust industry.

  • 1(current)

What type of business is Denali Therapeutics?

Denali Therapeutics Inc. specializes in developing methods for treating patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and others. Denali Therapeutics was registered in 2013, with its headquarters located in South San Francisco, California. In the Company's diversified portfolio, drug development is based on scientific understanding of the genetic causes and biological processes underlying neurodegenerative diseases. The company is conducting research programs on the Lysosomal Function Pathway, Glial Nature Pathway, and Cellular Homeostasis Pathway. Its candidate drugs include DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

What sector is Denali Therapeutics in?

Denali Therapeutics is in the Healthcare sector

What industry is Denali Therapeutics in?

Denali Therapeutics is in the Biotechnology industry

What country is Denali Therapeutics from?

Denali Therapeutics is headquartered in United States

When did Denali Therapeutics go public?

Denali Therapeutics initial public offering (IPO) was on 08 December 2017

What is Denali Therapeutics website?

https://www.denalitherapeutics.com

Is Denali Therapeutics in the S&P 500?

No, Denali Therapeutics is not included in the S&P 500 index

Is Denali Therapeutics in the NASDAQ 100?

No, Denali Therapeutics is not included in the NASDAQ 100 index

Is Denali Therapeutics in the Dow Jones?

No, Denali Therapeutics is not included in the Dow Jones index

When was Denali Therapeutics the previous earnings report?

No data

When does Denali Therapeutics earnings report?

The next expected earnings date for Denali Therapeutics is 27 February 2025